reports
Seer Technology Access Center Provides Unprecedented Scale and Depth o...
Seer Technology Access Center Provides Unprecedented Scale and Depth of Coverage for PrognomiQ’s Early Cancer Detection Study Combined Workflow of Proteograph™ XT Assay and Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer Robustly Identifies over 13,000 Protein Groups Across a Study of 2,840 Subjects REDWOOD CITY, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced today that PrognomiQ has completed the largest and deepest unbiased mass spectrometry plasma biomarker...
Puma Biotechnology Announces Presentation of Findings from a Phase II ...
LOS ANGELES--(BUSINESS WIRE)-- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, human epidermal growth factor receptor 2-negative (HER2-negative), hormone receptor-positive metastatic breast cancer (TBCRC 041; Clinicaltrials.gov identifier NCT02860000) at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting currently being held in Chic...
Nanobiotix Announces New Data Showing Disease Control and Tumor Respon...
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy Data show favorable safety and feasibility in 68 heavily pre-treated patients with R/M-HNSCC (Intention-to-Treat population; “ITT”) who received RT-activated NBTXR3 followed by anti-PD-1 as a second-or-later line treatment48% ORR in evaluable anti-PD-1 naïve patients (n=25); 28% ORR in evaluable anti-PD-1 resistant patients (n=25) as per RECIST 1.176% DCR in evaluable naïve patients; 68% DC...
Nanobiotix annonce de nouvelles données montrant un contrôle de la mal...
Nanobiotix annonce de nouvelles données montrant un contrôle de la maladie et une réponse tumorale chez des patients traités avec NBTXR3 activé par radiothérapie suivi d’un anti-PD-1, comme traitement de deuxième intention ou plus, dans le cancer de la tête et du cou récurrent ou métastatique, naïf ou résistant aux anti-PD-1 Traitement faisable et bien toléré chez 68 patients fortement prétraités atteints de CETEC-R/M (population en intention de traiter, ITT) qui ont reçu NBTXR3 activé par radiothérapie suivi d’un anti-PD-1 comme traitement de deuxième intention ou plus, en cohérence avec l...
ALX Oncology Presents First Evorpacept Combination Data with an Antibo...
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer Evorpacept in combination with PADCEV®, an approved antibody-drug conjugate (“ADC”), demonstrated promising activity and was generally well toleratedCompany to host conference call and webcast with Samuel A. Funt, M.D., of Memorial Sloan Kettering Cancer Center on Friday, June 7, 2024, at 1:00 PM ET SOUTH SAN FRANCISCO, Calif., June 02, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (N...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements...
Celldex Therapeutics Presents Data Demonstrating Profound Improvements in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2024 - Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups -- Sustained activity with rapid onset within 2 weeks -- Data further support barzolvolimab clinical benefit to patients with CSU - HAMPTON, N.J., June 02, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improve...
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Appl...
NVIDIA Enables Real-Time Healthcare, Industrial and Scientific AI Applications at the Edge With Enterprise Software Support for NVIDIA IGX With Holoscan Medtronic, SETI Institute, Manufacturing Leaders and More Build NVIDIA IGX Systems to Supercharge AI at the Industrial Edge TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- To address the increasing need for real-time AI computing at the industrial edge, NVIDIA today announced the general software availability of NVIDIA AI Enterprise-IGX with on the . Together, they empower solution providers within the medical, industrial...
- ABGSC Shipping & Transport Research
- Oliver Dunvold
- Petter Haugen
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of...
NVIDIA Robotics Adopted by Industry Leaders for Development of Tens of Millions of AI-Powered Autonomous Machines BYD Electronics, Siemens, Teradyne Robotics and Intrinsic, an Alphabet Company, Using NVIDIA Isaac Robotics Platform for Autonomous Robot Arms, Humanoids, Mobile Robots TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s leaders in robot development are adopting the for the research, development and production of the next generation of AI-enabled autonomous machines and robots. BYD Electronics, Siemens, Teradyne Robotics an...
Robotic Factories Supercharge Industrial Digitalization as Electronic ...
Robotic Factories Supercharge Industrial Digitalization as Electronic Makers Adopt NVIDIA AI and Omniverse NVIDIA Omniverse, Isaac and Metropolis Enable Delta Electronics, Foxconn, Pegatron, Wistron to Digitally Build, Simulate and Operate Factory Digital Twins TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that major Taiwanese electronics makers are using the company’s technology to transform their factories into more autonomous facilities with a new reference workflow. The workflow combines vision AI, ™ physically based rendering and simulation, ...
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs
NVIDIA Brings AI Assistants to Life With GeForce RTX AI PCs Project G-Assist, NVIDIA ACE NIMs for Digital Humans, and Generative AI Tools Deliver Advanced AI Experiences on RTX Laptops; Plus, RTX-Accelerated APIs for Small Language Models Coming to Windows Copilot Runtime TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced new ™ technology to power AI assistants and digital humans running on new ™ AI laptops. NVIDIA unveiled Project G-Assist — an RTX-powered AI assistant technology demo that provides context-aware help for PC games and apps. The Project...
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers ...
Computer Industry Joins NVIDIA to Build AI Factories and Data Centers for the Next Industrial Revolution Top Computer Manufacturers Unveil Array of Blackwell-Powered Systems Featuring Grace CPUs, NVIDIA Networking and InfrastructureBroad Portfolios Encompass Cloud, On-Premises, Embedded and Edge AI SystemsOfferings Range From Single to Multi-GPUs, x86 to Grace, Air to Liquid Cooling TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA and the world’s top computer manufacturers today unveiled an array of NVIDIA Blackwell architecture-powered systems featuring Grace CPUs, N...
NVIDIA Supercharges Ethernet Networking for Generative AI
NVIDIA Supercharges Ethernet Networking for Generative AI Spectrum-X Adopted by Cloud Service Providers, GPU Cloud Providers and Enterprises; Broad System-Maker Support Extends NVIDIA Networking’s Reach to Every Market TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced widespread adoption of the as well as an accelerated product release schedule. CoreWeave, GMO Internet Group, Lambda, Scaleway, STPX Global and Yotta are among the first AI cloud service providers embracing NVIDIA Spectrum-X to bring extreme networking performance to their AI infras...
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform...
NVIDIA NIM Revolutionizes Model Deployment, Now Available to Transform World’s Millions of Developers Into Generative AI Developers 150+ Partners Across Every Layer of AI Ecosystem Embedding NIM Inference Microservices to Speed Enterprise AI Application Deployments From Weeks to MinutesNVIDIA Developer Program Members Gain Free Access to NIM for Research, Development and Testing TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced that the world’s 28 million developers can now download ™ — inference microservices that provide models as optimized cont...
NVIDIA Releases Digital Human Microservices, Paving Way for Future of ...
NVIDIA Releases Digital Human Microservices, Paving Way for Future of Generative AI Avatars NVIDIA ACE Now Generally Available for Cloud, in Early Access for RTX AI PCs, in Use by Companies Across Customer Service, Gaming and Healthcare, Including Dell Technologies, ServiceNow, Aww Inc., Inventec, Perfect World Games TAIPEI, Taiwan, June 02, 2024 (GLOBE NEWSWIRE) -- COMPUTEX -- NVIDIA today announced the of NVIDIA ACE generative AI microservices to accelerate the next wave of digital humans, as well as new generative AI breakthroughs coming soon to the platform. Companies in cus...
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing P...
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE) Extended follow-up data reaching over two years in the earliest patients dosed reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema (HAE)Eight of 10 patients remain completely attack-free following the 16-week primary observation period through the latest follow-up, including patients with the most severe diseaseSingle dose of NTLA-2002 led to a 98% mean r...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack...
BioCryst Presents New Real-world Evidence Showing Reductions in Attack Rates in HAE Patients with Normal C1-Inhibitor after Beginning ORLADEYO® (berotralstat) Treatment Additional results from largest body of evidence on attenuated androgen use in HAE reinforce need for access to safer and more tolerable HAE prophylaxis options RESEARCH TRIANGLE PARK, N.C., June 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: BCRX) today announced new real-world evidence showing that patients with hereditary angioedema (HAE) who have normal C1-inhibitor (HAE-nC1-INH) level and function had a reduction in monthly...
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them...
Heineken® Celebrates Thousands of ‘Real Hardcore Fans’ by Helping Them Take Part in the UEFA Champions League Final Trophy Celebrations For The First Time Ever Heineken® says cheers to the Real Hardcore Fans as thousands of fans faces adorn the celebration confetti during the UEFA Champions League Final 2024 Trophy Lift at Wembley LONDON, June 01, 2024 (GLOBE NEWSWIRE) -- Tonight, Heineken® has created a way for thousands of ‘real hardcore fans’ to take part in the UEFA Champions League Final Trophy celebration, marking the culmination of the ‘’ 2024 campaign. Following the fina...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Dur...
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant Cohort In 17 EGFR wild-type (EGFRwt) non-small cell lung cancer (NSCLC) patients who failed chemotherapy and PD-1/PD-L1, AFM24 plus atezolizumab achieved 4 objective responses; 3 of 4 responses were ongoing for more than 7 months and progression free survival (PFS) was 5.9 monthsObjective responses were also seen in 4 of 13 response-evaluable EGFR mutant (EGFRmut) NSCLC patients confirming the activity o...
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in ...
Phase-2-Daten für Prüfpräparat Acasunlimab (DuoBody® -PD-L1x4-1BB) in Kombination mit Pembrolizumab: Signifikante klinische Aktivität bei vorbehandeltem, metastasiertem nicht-kleinzelligem Lungenkarzinom Erste Daten aus einer laufenden Phase-2-Studie zeigten eine 12-Monats-Gesamtüberlebensrate von 69 % und ein medianes Gesamtüberleben von 17,5 Monaten bei Patientinnen und Patienten mit vorbehandeltem, PD-L1-positivem, metastasiertem nicht-kleinzelligem Lungenkarzinom, die alle sechs Wochen mit einer Kombination aus Acasunlimab und Pembrolizumab behandelt wurden.Die Daten der laufenden Phase...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.